Safety and efficacy of niraparib in pts. ≥70 years are similar to younger population.
Introduction
Ovarian cancer is the fifth leading cause of cancer-related death in women and the leading cause of death from gynecological malignancies [1] . The median age for ovarian cancer diagnosis is 63 years, and approximately one-third of patients with ovarian cancer are ≥70 years [2] . Increased age and factors associated with advanced age (advanced International Federation of Gynecology and Obstetrics [FIGO] stage, comorbid status, and poor tumor cytoreducibility) have been found to be independent prognostic factors of survival for patients with ovarian cancer [3] [4] [5] .
Studies have shown that older patients are able to tolerate cytoreductive surgery and chemotherapy with safety and efficacy comparable to that of younger patients, with an independent effect of age on survival in older patients receiving standard-of-care treatment [6] [7] [8] [9] . National Comprehensive Cancer Network (NCCN) guidelines for older patients (≥65 and ≥ 70 years) recommend the same standard-of-care treatment as for the general population but note that older patients may be at higher risk of severe toxicities and have a higher rate of treatment discontinuation [10] . A recent randomized, placebo-controlled, pivotal phase 3 study conducted in patients with recurrent ovarian cancer (ENGOT-OV16/NOVA; NCT01847274) demonstrated significantly longer progression-free survival (PFS) in patients receiving niraparib than in those receiving placebo [11] . NCCN guidelines recommend maintenance treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor such as niraparib following a complete response (CR) or partial response (PR) to secondline or later treatment with platinum-based chemotherapy.
Hematologic adverse events (AEs) were classified as AEs of special interest (AESI) in the ENGOT-OV16/NOVA study, and they are of particular concern in the older population due to the reduction of hematopoietic reserves in this population [12] . Here we present a retrospective subanalysis on the safety and efficacy of niraparib in the subgroup of patients aged ≥70 years in the ENGOT-OV16/NOVA trial.
Patients and methods
The ENGOT-OV16/NOVA study design has previously been published [11] . The ENGOT-OV16/NOVA trial enrolled 2 independent cohorts on the basis of germline breast cancer susceptibility gene mutation (gBRCAmut) status (determined by BRACAnalysis Testing, Myriad Genetics, Salt Lake City, UT, USA). Patients were at least 18 years of age and had histologically diagnosed recurrent ovarian, fallopian tube, or peritoneal cancer. All patients had disease progression N6 months after completion of their penultimate platinum-based round of chemotherapy. Patients also had to have achieved a CR or PR to their last platinum-based chemotherapy prior to being randomized in the study.
Patients in each cohort (gBRCAmut and non-gBRCAmut) were randomized 2:1 to receive niraparib (300 mg) or placebo once daily until disease progression. Randomization within each cohort was stratified based on time to progression following the penultimate platinum-based regimen, prior use of bevacizumab, and best response (CR or PR) to the last platinum-based regimen. The primary endpoint was duration of PFS as determined by blinded independent central review.
For this analysis, patients were dichotomized according to an age split of b70 or ≥ 70 years based on age at time of study entry. The decision to use 70 as the defining age was based on clinical relevance and established guidelines [10, 13] . The objective of this analysis was to evaluate the safety and efficacy of niraparib in older patients. AESI assessed included hematologic toxicities, fatigue, pneumonitis, and overdose. Patient-reported outcomes were examined using the Functional Assessment of Cancer Therapy-Ovarian Symptoms Index (FOSI) and European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) questionnaires.
Results

Baseline characteristics
The baseline characteristics of the general population were previously reported [11] . Baseline demographics were generally well balanced between the age groups (Table 1) . Of the 553 patients in the study, 95 (17%) were aged ≥70 years and 31 (6%) were aged ≥75 years. The median age in the ≥70 years subgroup was 74 years in the niraparib arm and 72 years in the placebo arm. In both arms, patients aged ≥70 years were more likely to have progressed b12 months after the penultimate platinum-based therapy and to have had a PR to their last platinumbased therapy compared with younger patients.
Efficacy
The primary efficacy readouts were previously reported [11] . Briefly, maintenance treatment with niraparib extended PFS in both the gBRCAmut cohort (hazard ratio [HR], 0.27 [95% confidence interval (CI), 0.17 to 0.41]) and overall non-gBRCAmut cohort (HR, 0.45 [95% CI, 0.34 to 0.61]) [11] .
In the gBRCAmut cohort, patients aged b70 years receiving niraparib had a median PFS of 15.5 months compared with a median PFS of 5.8 months for the same age group in the placebo arm (HR, 0.30 [95% CI, 0.19 to 0.47]; Fig. 1A and B ). Patients aged ≥70 years in the gBRCAmut cohort receiving niraparib had not yet reached a median PFS compared with a median PFS of 3.7 months for the same age group in the placebo arm (HR, 0.09 [95% CI, 0.01 to 0.73]).
In the non-gBRCAmut cohort, patients aged b70 years receiving niraparib had a median PFS of 7.5 months compared with a median PFS of 3.9 months for the same age group in the placebo arm (HR, 0.47 [95% CI, 0.34 to 0.66]; Fig. 1A and B ), a 53% reduction in risk of progression. Patients aged ≥70 years in the non-gBRCAmut cohort receiving niraparib had a median PFS of 11.3 months compared with a median PFS of 3.8 months for the same age group in the placebo arm (HR, 0.35 [95% CI, 0.18 to 0.71]), a 65% reduction in risk of progression.
Safety
AEs for the NOVA population by age are summarized in Tables 2,  3, and Supplemental Table S1 , and the full list of AEs for the ENGOT-OV16/NOVA study were previously reported [11] . In the niraparib arm, the frequency and severity of serious treatment-emergent AEs (TEAEs) were similar regardless of age ( Fig. 2 and Table 2 ). The most common AEs of any grade were nausea, thrombocytopenia events, fatigue events, anemia events, constipation, and vomiting.
Of the AESI, the incidence of myelosuppression events was higher in the niraparib arm than in the placebo arm but showed no agerelated difference (75.5% and 78.7% with niraparib vs. 20.0% and 11.8% with placebo; Supplemental Table S2 ). In the niraparib arm, thrombocytopenia events were slightly more frequent in patients aged ≥70 years (65.6%) than in those aged b70 years (60.5%), while leukopenia events (32.8% vs. 35.6%), neutropenia events (24.6% vs. 31.4%), and fatigue events (55.7% vs. 60.1%) were slightly less frequent in patients aged ≥70 years compared with patients aged b70 years ( Fig. 3 and Supplemental Table S2 ). The incidence of anemia events was similar among patients aged ≥70 years (49.2%) and b 70 years (50.3%). The incidence of grade ≥3 TEAEs was approximately similar for patients in the niraparib arm, regardless of age (≥70 years, 70.5%; b70 years, 74.8%; Table 2 ). No grade 5 TEAEs were reported in the niraparib or placebo arms. In the niraparib arm, dose reduction rates were similar regardless of age (≈69% in both cohorts; Table 2 ). Dose interruptions were less common in patients aged ≥70 years (55.7%) than in those aged b70 years (68.6%). By contrast, treatment discontinuations were more common in patients aged ≥70 years (19.7%) than in those aged b70 years (13.7%) ( Supplemental Table S3 provides further details on dose discontinuations in patients aged ≥70 years receiving niraparib).
In the niraparib arm, the most common grade ≥3 TEAEs among patients aged ≥70 and b70 years, respectively, were thrombocytopenia events (34.4% and 33.7%; Table 3 ), anemia events (13.1% and 27.8%), neutropenia events (16.4% and 20.3%), hypertension (6.6% and 8.5%), and fatigue events (8.2% and 8.2%).
Patient-reported outcomes
Analysis of FOSI scores by age did not reveal any specific quality of life differences in patients aged ≥70 years when compared with patients aged b70 years (Fig. 4) . The tendency for great volatility (higher highs, lower lows, and larger wings) is likely due to the smaller group size, as this trend was also evident in patients receiving placebo. EQ-5D-5L utility scores were similar regardless of patient age ( Supplemental  Table S4 ).
Discussion
The study demonstrates that for older patients receiving niraparib as a maintenance treatment in the ENGOT-OV16/NOVA trial, PFS benefits and the incidence of any grade or serious TEAEs were comparable to the results seen in the younger population. Maintenance treatment with niraparib was associated with hematologic toxicities, but rates of any grade or grade ≥ 3 myelosuppressive TEAEs were similar among patients aged b70 and ≥70 years.
While the ENGOT OV-16/NOVA population comprised patients with both gBRCAmut and non-gBRCAmut disease, previously published data on the safety of olaparib in older patients are limited to patients with gBRCA mutations. In these patients, Dockery et al. reported no special safety concerns in older patients relative to younger patients [14] . Our results with niraparib are concordant with this and further demonstrate the safety of PARP inhibitors in non-gBRCAmut patients who tend to be older. This study also provides efficacy data for niraparib in both populations.
A similar analysis that includes both patients with gBRCAmut and non-gBRCAmut ovarian cancer has been previously published for platinum/taxane chemotherapy in the AGO OVAR-3 study, which found that although rates of hematologic AEs were similar for patients aged b70 and ≥ 70 years, there were significantly more reports of febrile neutropenia among patients aged ≥70 years [8] . We did not find an increase in febrile neutropenia in older patients receiving niraparib.
The use of PARP inhibitors has the potential to increase the chemotherapy-free interval in patients [11, 15] , which may be advantageous in older patients, who are often unable to receive successive lines of chemotherapy following progression due to comorbidities [7] . In this analysis, two-thirds of discontinuations in patients aged ≥70 years were for grade 1 or 2 AEs. The lower level of treatment interruptions and higher level of discontinuations in patients aged ≥70 years may indicate an investigator bias toward treatment discontinuations in older patients. A similar pattern suggesting investigator bias in discontinuation rates has previously been noted for doublet chemotherapy in patients aged ≥70 years [8] .
In both cohorts, we observed a reduced risk with niraparib in patients aged ≥70 years compared with the younger patients. While this could be associated with a genetic driver, such as the well-known increase in p53 mutations with age [16] , this result should be interpreted with caution. The ENGOT-OV16/NOVA trial was not designed with a prespecified geriatric assessment, and there were low numbers of patients ≥70 years of age in either cohort; therefore, the results are descriptive in nature. Further results from real-world treatment of older patients will be necessary to establish any benefit beyond the increased PFS observed in the ENGOT-OV16/NOVA trial.
There are other limitations of this post hoc analysis. Approximately 20% of the ENGOT-OV16/NOVA study population were ≥70 years of age, less than the 30% approximated for the total ovarian cancer population [2] . This discrepancy may be due to a number of factors: clinician bias against referring older patients for clinical trial enrollment, greater incidence of comorbidities in patients ≥70 years of age, and ineligibility for enrollment in this trial due to exclusion criteria. Additionally, patients enrolled in ENGOT-OV16/NOVA were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, a factor more likely to exclude older patients.
In the ENGOT-OV16/NOVA study, niraparib treatment significantly prolonged PFS in patients with recurrent ovarian cancer. The safety and efficacy of niraparib in patients aged ≥70 years were comparable to the results observed for the younger population. This study provides encouraging results that older patients who meet the criteria for ENGOT-OV16/NOVA can benefit from the same standard-of-care therapy as younger patients.
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